JP2023506642A5 - - Google Patents
Info
- Publication number
- JP2023506642A5 JP2023506642A5 JP2022537250A JP2022537250A JP2023506642A5 JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5 JP 2022537250 A JP2022537250 A JP 2022537250A JP 2022537250 A JP2022537250 A JP 2022537250A JP 2023506642 A5 JP2023506642 A5 JP 2023506642A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidine
- dione
- methoxy
- oxoisoindorin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950048P | 2019-12-18 | 2019-12-18 | |
| US62/950,048 | 2019-12-18 | ||
| PCT/IB2020/062070 WO2021124172A1 (en) | 2019-12-18 | 2020-12-16 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506642A JP2023506642A (ja) | 2023-02-17 |
| JP2023506642A5 true JP2023506642A5 (cg-RX-API-DMAC7.html) | 2024-01-30 |
| JP7682181B2 JP7682181B2 (ja) | 2025-05-23 |
Family
ID=73856242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537250A Active JP7682181B2 (ja) | 2019-12-18 | 2020-12-16 | 3-(5-メトキシ-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
Country Status (23)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186926A1 (en) * | 2020-08-07 | 2022-02-10 | Francis Barany | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| JP7744061B2 (ja) * | 2021-07-30 | 2025-09-25 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用 |
| US20240124412A1 (en) * | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN120129677A (zh) | 2022-11-04 | 2025-06-10 | 百时美施贵宝公司 | 化合物及其用于治疗血红素病变的用途 |
| EP4644382A4 (en) * | 2022-12-27 | 2026-04-01 | Gluetacs Therapeutics Shanghai Co Ltd | ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE |
| CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| TW202530209A (zh) * | 2023-10-06 | 2025-08-01 | 美商德爾菲亞治療股份有限公司 | 化合物、其醫藥組合物及其使用方法 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025137613A1 (en) * | 2023-12-22 | 2025-06-26 | Ganymede Oncology, Inc. | Cycloalkylene nrf2 protein degraders |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| CN120717945A (zh) * | 2025-08-15 | 2025-09-30 | 泰迩生物医药泰州有限公司 | 一种(2r,4s)-n-boc-4-羟基哌啶-2-甲酸甲酯的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖rna仲介遺伝子抑制 |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2014018866A1 (en) | 2012-07-27 | 2014-01-30 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| WO2017185031A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3676268A1 (en) | 2017-10-20 | 2020-07-08 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificityfor the bromodomain of brd4 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019177902A1 (en) | 2018-03-10 | 2019-09-19 | Yale University | Modulators of btk proteolysis and methods of use |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CA3102212A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| AU2019294835B2 (en) | 2018-06-29 | 2025-04-17 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
| EP3814380A4 (en) | 2018-06-29 | 2022-06-15 | Dana Farber Cancer Institute, Inc. | BISPECIFIC DEGRADATION PRODUCTS |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| CN113490495B (zh) | 2018-12-03 | 2024-09-27 | 达纳-法伯癌症研究公司 | Helios的小分子降解剂及其使用方法 |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
-
2020
- 2020-12-16 PH PH1/2022/551482A patent/PH12022551482A1/en unknown
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en not_active Abandoned
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en not_active Ceased
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es not_active Application Discontinuation
- 2020-12-16 PY PY202002084899A patent/PY2084899A/es unknown
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko not_active Withdrawn
- 2020-12-16 JP JP2022537250A patent/JP7682181B2/ja active Active
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 UY UY0001038986A patent/UY38986A/es not_active Application Discontinuation
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 ES ES20828350T patent/ES2980575T3/es active Active
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-06-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| US11964953B2 (en) | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | |
| JP6409081B2 (ja) | 治療活性化合物およびその使用方法 | |
| CA2984259C (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| US11304946B2 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | |
| US10028961B2 (en) | Therapeutically active compounds and their methods of use | |
| CA2956992C (en) | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | |
| JP2024521618A5 (cg-RX-API-DMAC7.html) | ||
| JP5687903B2 (ja) | キヌレニン産生抑制剤 | |
| JP2017500364A5 (cg-RX-API-DMAC7.html) | ||
| JP2023525762A5 (cg-RX-API-DMAC7.html) | ||
| TW201840549A (zh) | 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺 | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| JP2013523819A5 (cg-RX-API-DMAC7.html) | ||
| US10894784B2 (en) | Heteroarylbenzimidazole compounds | |
| AU2022258751A1 (en) | Phosphorus derivatives as novel sos1 inhibitors | |
| US20240174683A1 (en) | Map4k1 inhibitors | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| US9695198B2 (en) | Factor IXa inhibitors | |
| US20240383875A1 (en) | Benzimidazole Pyridine Derivatives | |
| US20230405015A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| JP2023550902A5 (cg-RX-API-DMAC7.html) | ||
| RU2023130418A (ru) | Гетероциклические соединения | |
| EA048085B1 (ru) | Замещенные аминотиазолы в качестве ингибиторов dgkzeta для иммунной активации |